---
figid: PMC10364493__znac452f1
pmcid: PMC10364493
image_filename: znac452f1.jpg
figure_link: /pmc/articles/PMC10364493/figure/znac452-F1/
number: Fig. 1
figure_title: ''
caption: Modes of response evaluation of neoadjuvant therapy in pancreatic cancera
  Diagnostic and staging pathway before neoadjuvant therapy; b conventional and emerging
  ways of evaluating response, either before surgery or after surgery, with advantages
  and disadvantages. A combination of methods will likely to be used in the future
  to best evaluate response at baseline, at interim evaluation, and after completion
  of therapy. PDAC, pancreatic ductal adenocarcinoma; CA19-9, carbohydrate antigen
  19-9; ECOG, Eastern Cooperative Oncology Group performance status; NGS, next-generation
  sequencing; ctDNA, circulating free tumour DNA.
article_title: Call for better response evaluation after neoadjuvant therapy in pancreatic
  cancer.
citation: Claudia Zaharia, et al. Br J Surg. 2023 Mar;110(3):294-296.
year: '2023'

doi: 10.1093/bjs/znac452
journal_title: The British Journal of Surgery
journal_nlm_ta: Br J Surg
publisher_name: Oxford University Press

keywords:
---
